Senti Biosciences (SNTI) EPS (Weighted Average and Diluted) (2021 - 2025)
Senti Biosciences' quarterly EPS (Weighted Average and Diluted) came in at -$0.48 in Q4 2025, up 22.58% year-on-year from -$0.39 in Q4 2024, and up 30.43% quarter-over-quarter from -$0.69 in Q3 2025.
Senti Biosciences has reported EPS (Weighted Average and Diluted) for 5 years, with the latest figure at -$0.48 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 22.58% year-over-year to -$0.48; the trailing twelve-month figure through Dec 2025 stood at -$3.14 (up 73.9% YoY), and the FY2025 full-year result was -$2.73, up 77.31% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$0.48, up from -$0.69 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.09 in Q4 2022, with the low at -$6.98 in Q4 2023.
- Average EPS (Weighted Average and Diluted) over 5 years is -$2.46, with a median of -$2.45 recorded in 2024.
- Year-over-year, EPS (Weighted Average and Diluted) surged 102.45% in 2022 and sank 7855.56% in 2023.
- Tracing SNTI's EPS (Weighted Average and Diluted) over 5 years: stood at -$3.67 in 2021, then surged by 102.45% to $0.09 in 2022, then slumped by 7855.56% to -$6.98 in 2023, then surged by 91.12% to -$0.62 in 2024, then advanced by 22.58% to -$0.48 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.48 (Q4 2025), -$0.69 (Q3 2025), and -$0.56 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.48 |
| Sep 30, 2025 | -0.69 |
| Jun 30, 2025 | -0.56 |
| Mar 31, 2025 | -1.41 |
| Dec 31, 2024 | -0.62 |
| Sep 30, 2024 | -6.31 |
| Jun 30, 2024 | -2.45 |
| Mar 31, 2024 | -2.65 |
| Dec 31, 2023 | -6.98 |
| Sep 30, 2023 | -3.36 |
| Jun 30, 2023 | -4.22 |
| Mar 31, 2023 | -0.42 |
| Dec 31, 2022 | 0.09 |
| Sep 30, 2022 | -0.38 |
| Jun 30, 2022 | -0.86 |
| Mar 31, 2022 | -3.72 |
| Dec 31, 2021 | -3.67 |
| Sep 30, 2021 | -3.90 |
| Jun 30, 2021 | -4.13 |